Investment leads to accessible sleep research and reduced healthcare costs

This funding round was led by new investors EQT Life Sciences, along with another new investor, Gimv. Alongside Invest-NL, existing investors such as Innovation Industries, imec.xpand, BOM, and 15th Rock participated in this equity round.

This capital infusion enables Onera Health to accelerate its production and implementation plans. Furthermore, the company aims to use these resources to expedite the approval of its second-generation polysomnography (PSG) system in Europe and the United States, further positioning itself as a market leader in diagnostic technology for sleep medicine.

Investing in healthcare transition

Invest-NL is committed to keeping healthcare accessible, affordable, and staffable. Part of this commitment includes making complex research methodologies available to a broader group of patients. This technology also partly shifts the most limited and expensive form of healthcare, that in hospitals, to the patients' home environment.

Investment manager Bram Sprangers commented: “We are delighted that two more leading life science investors have joined to accelerate the development and market rollout of this technology. The revolutionary nature of Onera’s solution is a game-changer in the field of diagnostics for sleep disorders. We are impressed by what the Onera Health management has achieved so far and look forward to future developments.”

We previously published a storyabout our investment in Onera Health.